Lung Carcinoid Tumors: Diagnosis, Staging and Treatment Options

A lung carcinoid tumor is a rare type of neuroendocrine tumor that develops from hormone-producing cells in the lungs. These tumors tend to grow more slowly than other lung cancers and are classified as typical or atypical based on how aggressive the cells appear under a microscope. While many lung carcinoid tumors are diagnosed at an early stage, some patients are not diagnosed until the disease has spread.

Because lung carcinoid tumors behave differently from more common lung cancers, treatment decisions are based on tumor type, stage, symptoms and overall health rather than a one-size-fits-all approach. Long-term follow-up is often an important part of care.

What does a lung carcinoid tumor diagnosis look like?

Diagnosis often begins with imaging, such as a CT scan, prompted by symptoms like persistent cough, wheezing, shortness of breath, chest pain or repeated lung infections. Some tumors are discovered incidentally during imaging for other conditions.

A biopsy is required to confirm the diagnosis and determine whether the tumor is typical or atypical. This may be done through bronchoscopy, needle biopsy or surgery. Additional testing may include PET imaging or specialized scans for neuroendocrine tumors, along with blood or urine tests to assess hormone activity. Accurate staging is essential to guide treatment planning.

Treatment options by stage

Stage 1

Stage 1 lung carcinoid tumors are confined to the lung and have not spread to lymph nodes or distant organs. Tumors at this stage are typically small and localized, which often allows for curative treatment. Many patients are diagnosed at this stage, especially when tumors are found incidentally.

Frontline:
Surgery is usually the primary treatment, with the goal of completely removing the tumor while preserving lung function.

Second-Line:
Radiation therapy may be considered if surgery is not possible due to medical conditions or tumor location.

Third-Line and Beyond:
Routine surveillance with imaging is standard. Additional treatment is uncommon unless the cancer returns.

Stage 2

Stage 2 disease means the tumor may be larger or has spread to nearby lymph nodes within the lung. While the cancer remains localized, there is a higher risk of recurrence compared with stage 1.

Frontline:
Surgery remains the main treatment, often including removal of nearby lymph nodes to better assess spread.

Second-Line:
Radiation therapy may be recommended if the tumor cannot be fully removed or if there is concern for remaining cancer cells.

Third-Line and Beyond:
Close monitoring is typical. Further treatment may be discussed if there are signs of progression.

Stage 3

Stage 3 lung carcinoid tumors have spread to lymph nodes in the chest or involve nearby structures. At this stage, treatment is more complex and often requires a combination approach. Cure may still be possible for some patients, depending on how far the disease has spread and how it responds to treatment.

Frontline:
Treatment may include surgery, radiation therapy or both, depending on tumor location and lymph node involvement.

Second-Line:
Systemic therapies, such as somatostatin analogs, may be used to slow tumor growth and manage hormone-related symptoms.

Third-Line and Beyond:
Additional systemic therapies or clinical trial options may be considered if the disease progresses.

Explaining metastatic lung carcinoid tumors

Metastatic lung carcinoid tumors have spread beyond the lungs to distant organs, such as the liver, bones or other parts of the body. While metastatic disease is not typically curable, many patients live for years with ongoing treatment and monitoring.

Frontline:
Systemic therapy is the primary approach. Somatostatin analogs are commonly used to control tumor growth and symptoms.

Second-Line:
Targeted therapies or peptide receptor radionuclide therapy may be options for eligible patients.

Third-Line and Beyond:
Chemotherapy or participation in clinical trials may be discussed based on tumor behavior and prior treatments.

Side effects from lung carcinoid tumor treatment

Side effects depend on the treatment used. Surgery may lead to temporary pain, fatigue or breathing changes. Radiation therapy can cause skin irritation, cough or lung inflammation.

Systemic therapies may cause gastrointestinal symptoms, fatigue or changes in blood sugar levels. Patients are encouraged to report side effects early so their care team can provide supportive treatment and make adjustments when needed.

Conclusion

A lung carcinoid tumor diagnosis can raise many questions, especially given how rare the disease is. Outcomes are often favorable, particularly for patients diagnosed at earlier stages, and treatment strategies are tailored to each individual. Understanding the stage of disease helps patients and oncologists align on goals of care and next steps.

Open communication with the care team is essential throughout the cancer journey. Patients are encouraged to ask about treatment options, side effects, follow-up care and whether clinical trials may be appropriate at any stage.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.